Herriot Tabuteau

About Me

Herriot Tabuteau founded Axsome Therapeutics in 2012 with the goal of developing life-changing treatments for the millions of patients living with brain disorders. Tabuteau owns 15% of Axsome, which he took public in 2015. Prior to founding the company, Tabuteau worked in healthcare finance, including as a partner at hedge fund Healthco/S.A.C. Capital. He is the inventor on more than 200 patents, including potential new medicines for depression, behavior disturbances in Alzheimer's disease and narcolepsy. Axsome's drug Symbravo (meloxicam and rizatriptan) received FDA approval in January 2025 for the acute treatment of migraines with or without auras. Its drug AXS-05 for the treatment of Alzheimer's disease agitation received a Breakthrough Therapy designation from the FDA in 2020. It now plans to submit a supplemental new drug application for it.